ADCY3

Across TCGA pan-cancer cohorts, ADCY3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADCY3 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ADCY3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ADCY3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

LUAD, LSCC, and CCRCC are the cancer types where ADCY3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.285	0.808	.023	6	view →
LSCC	DFS	Quartile	II,III,IV	0.927	0.572	.038	2	view →
CCRCC	DFS	Median	II,III,IV	1.000	0.598	.040	1	view →
HNSC	OS	Quartile	II,III,IV	0.964	0.812	.030	1	view →
GBM	OS	Tertile	All	0.915	0.728	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ADCY3–LUAD (OS)

Open the LUAD breakdown →